Wave Life Sciences (NASDAQ:WVE – Get Rating) and Day One Biopharmaceuticals (NASDAQ:DAWN – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, profitability, valuation and risk.
Valuation & Earnings
This table compares Wave Life Sciences and Day One Biopharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Wave Life Sciences||$40.96 million||3.57||-$122.25 million||($2.13)||-1.12|
|Day One Biopharmaceuticals||N/A||N/A||-$70.64 million||N/A||N/A|
Day One Biopharmaceuticals has lower revenue, but higher earnings than Wave Life Sciences.
Volatility & Risk
This is a breakdown of recent recommendations and price targets for Wave Life Sciences and Day One Biopharmaceuticals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Wave Life Sciences||0||0||1||0||3.00|
|Day One Biopharmaceuticals||0||0||2||0||3.00|
Wave Life Sciences currently has a consensus price target of $8.00, suggesting a potential upside of 234.73%. Day One Biopharmaceuticals has a consensus price target of $37.50, suggesting a potential upside of 128.10%. Given Wave Life Sciences’ higher possible upside, equities research analysts clearly believe Wave Life Sciences is more favorable than Day One Biopharmaceuticals.
This table compares Wave Life Sciences and Day One Biopharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Wave Life Sciences||-275.31%||-558.73%||-60.21%|
|Day One Biopharmaceuticals||N/A||-28.94%||-28.26%|
Insider and Institutional Ownership
78.7% of Wave Life Sciences shares are held by institutional investors. Comparatively, 79.0% of Day One Biopharmaceuticals shares are held by institutional investors. 32.2% of Wave Life Sciences shares are held by company insiders. Comparatively, 8.7% of Day One Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Day One Biopharmaceuticals beats Wave Life Sciences on 6 of the 10 factors compared between the two stocks.
About Wave Life Sciences
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.
About Day One Biopharmaceuticals
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.